204452-40-4

Upstream product

• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 10602-03-6 ethyl 4-ethynylbenzoate 
• 204452-34-6 N-(4-iodo-phenylsulfonylamino)-L-asparagine 
• 204452-35-7 3-amino-2(S)-4-iodophenylsulfonylaminopropionate 
• 298692-94-1 4-[2-(2-aminopyridin-6-yl)ethyl]benzoic acid 
• 150969-54-3 ethyl 4-(trimethylsilylethynyl)benzoate 
• 98-61-3 p-Iodobenzenesulfonyl chloride 
• 204452-39-1 3-{4-[2-(6-aminopyridin-6-yl)ethyl]benzoylamino}-2(S)-4-iodobenzenesulfonylaminopropionic acid ethyl ester 
• 204452-37-9 Ethyl 4-[2-(2-Aminopyridine-6-yl)ethyl]benzoate 
• 174665-68-0 ethyl 4-[2-(2-aminopyridin-6-yl)ethynyl]benzoate 

Relevant academic research and scientific papers

Dibenzoxazepine alpha v integrin receptor antagonist

The present invention relates to a novel dibenzoxazepine derivative, its synthesis, and its use as an αv integrin receptor antagonist. More particularly, the compound of the present invention is an antagonist of the integrin receptors αvβ3 and αvβ5 and th

Nonpeptide α(v)β3 antagonists. 1. Transformation of a potent, integrin-selective α(IIb)β3 antagonist into a potent α(v)β3 antagonist

Modification of the potent fibrinogen receptor (α(IIb)β3) antagonist 1 generated compounds with high affinity for the vitronectin receptor α(v)β3. Sequential modification of the basic N-terminus of 1 led to the identification of the